Amicus Therapeutics reported total revenue of $154.7 million for Q2 2025, a 22% increase over Q2 2024, with 18% growth at constant exchange rates.
Cash, cash equivalents, and marketable securities totaled $231 million as of June 30, 2025, down from $250 million at the end of 2024.
GAAP net loss was $24.4 million or $0.08 per share, compared to a net loss of $15.7 million or $0.05 per share in Q2 2024; excluding the DMX-200 payment, GAAP net income would have been positive.
GAAP operating expenses increased 48% to $148.9 million, including a $30 million upfront payment for DMX-200 licensing; non-GAAP operating expenses increased 56% to $127.8 million.
Galafold revenue reached $128.9 million, up 12% at constant exchange rates and 16% reported, driven by new patient starts and a 69% global market share for treated Fabry patients.
Non-GAAP net income was $1.9 million or $0.01 per share, down from $18.5 million or $0.06 per share in Q2 2024.
Pombiliti and Opfolda revenue was $25.8 million, up 58% at constant exchange rates, with strong sales growth and record patient demand across 11 countries.
Dafinchi